6AND
| Pinatuzumab Fab in complex with anti-Kappa VHH domain | Descriptor: | Anti-kappa VHH domain, GLYCEROL, Pinatuzumab Fab Heavy chain, ... | Authors: | Ereno-Orbea, J, Sicard, T, Julien, J.-P. | Deposit date: | 2017-08-12 | Release date: | 2018-01-31 | Last modified: | 2019-05-08 | Method: | X-RAY DIFFRACTION (1.75 Å) | Cite: | Structural Basis of Enhanced Crystallizability Induced by a Molecular Chaperone for Antibody Antigen-Binding Fragments. J. Mol. Biol., 430, 2018
|
|
6ANI
| Coltuximab Fab in complex with anti-Kappa VHH domain | Descriptor: | Anti-Kappa VHH domain, Coltuximab Fab heavy chain, Coltuximab Fab light chain, ... | Authors: | Ereno Orbea, J, Sicard, T, Julien, J.-P. | Deposit date: | 2017-08-13 | Release date: | 2018-01-31 | Last modified: | 2019-10-16 | Method: | X-RAY DIFFRACTION (2.4 Å) | Cite: | Structural Basis of Enhanced Crystallizability Induced by a Molecular Chaperone for Antibody Antigen-Binding Fragments. J. Mol. Biol., 430, 2018
|
|
6ANA
| LL2 Fab in complex with anti-Kappa VHH domain | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-[alpha-L-fucopyranose-(1-6)]2-acetamido-2-deoxy-beta-D-glucopyranose, LL2 Fab Heavy Chain, LL2 Fab Light Chain, ... | Authors: | Sicard, T, Ereno Orbea, J, Julien, J.-P. | Deposit date: | 2017-08-12 | Release date: | 2018-01-31 | Last modified: | 2020-07-29 | Method: | X-RAY DIFFRACTION (1.7 Å) | Cite: | Structural Basis of Enhanced Crystallizability Induced by a Molecular Chaperone for Antibody Antigen-Binding Fragments. J. Mol. Biol., 430, 2018
|
|